VOY-101 / Perceive Bio

1 to 6 Of 6 Go to page

April 23, 2024

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=140 | Recruiting | Sponsor: Perceive Biotherapeutics, Inc. | N=66 ➔ 140

Enrollment change • Metastases • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

April 11, 2024

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=45 | Active, not recruiting | Sponsor: Perceive Biotherapeutics, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

October 17, 2023

VOY-101 in Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=66 | Recruiting | Sponsor: Perceive Biotherapeutics, Inc.

Metastases • New P1/2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

November 22, 2022

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=45 | Recruiting | Sponsor: Perceive Biotherapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

September 29, 2022

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=45 | Not yet recruiting | Sponsor: Perceive Biotherapeutics, Inc. | Trial completion date: Jul 2026 ➔ Oct 2025 | Initiation date: Jul 2022 ➔ Oct 2022 | Trial primary completion date: Jul 2026 ➔ Oct 2025

Trial completion date • Trial initiation date • Trial primary completion date • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

May 19, 2022

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - P1/2 | N=35 | Not yet recruiting | Sponsor: Perceive Biotherapeutics, Inc.

New P1/2 trial • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

1 to 6 Of 6 Go to page